Blueprint Medicines — Q4 2024 Earnings Presentation
12 slides from Blueprint Medicines's earnings presentation, Feb 13, 2025
Slide 1: Blueprint Medicines
Blueprint Medicines Driving growth and innovation with operational excellence Fourth quarter and full-year 2024 financial results February 13, 2025
Slide 2: Fourth quarter and full-year 2024 financial results
Fourth quarter and full-year 2024 financial results AYVAKIT CLINICAL FINANCIAL INTRODUCTION PERFORMANCE PROGRESS RESULTS Kate Haviland Philina Lee, PhD Becker Hewes, MD Mike Landsittel Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding its plans, strategies, timelines and expectations for the company’s operations,
Slide 4: 2025 guidance progresses AYVAKIT toward $2 billion by 2030
2025 guidance progresses AYVAKIT toward $2 billion by 2030 $4,000 AYVAKIT REVENUE GROWTH ~45% $2,000 $, MILLIONS = Actual $680-710 = Expected $479 Implied ~24% CAGR (2025 midpoint to 2030 goal) $204 $111 $53 2021 2022 2023 2024 2025 2030 Franchise Peak 2025 guidance represents robust YoY growth cons
Slide 5: Our capital allocation strategy aligns with core growth drivers
Our capital allocation strategy aligns with core growth drivers HIGH GROWTH DURABLE FINANCIAL PROFILE Drive continued AYVAKIT Advance R&D innovation revenue growth to fuel long-term growth Extend long-term SM franchise with elenestinib development CONTINUOUS INNOVATION Accelerate and expand developm
Slide 6: AYVAKIT achieved 135% year-over-year growth in 2024
AYVAKIT achieved 135% year-over-year growth in 2024 Q4 2024 HIGHLIGHTS AYVAKIT 135% REVENUE $479 PATIENTS GROWTH • Continued growth in patients on therapy $, MILLIONS • Trend toward multi-year durations of therapy in ISM • ~95% strongly agree they are satisfied with AYVAKIT1 PAYERS $204 • Continued
Slide 7: Driving breadth and depth with significant headroom for continued growth
Driving breadth and depth with significant headroom for continued growth PRESCRIBING BREADTH PRESCRIBING DEPTH Cumulative prescribers with Cumulative prescribers with 1+ patients SM on therapy 2+ SM patients on therapy since ISM approval since ISM approval 2 patients 1 patient 3-4 patients 2+ patien
Slide 8: Building on our success to drive growth in 2025 and beyond
Building on our success to drive growth in 2025 and beyond Activate more patients and providers with new initiatives, including peer-to-peer and direct-to-consumer programs 2025 AYVAKIT Generate AYVAKIT and real-world data catalyzing urgency to treat investment priorities Launch ISM in additional ge
Slide 9: Updated AYVAKIT data support strong safety and efficacy profile
Updated AYVAKIT data support strong safety and efficacy profile plus positive impact on bone health AYVAKIT 3-YEAR FOLLOW-UP CLINICALLY MEANINGFUL DATA FROM PIONEER TRIAL 1 IMPROVEMENT IN BONE DENSITY 3 Lumbar Spine Femoral Neck Total Femur • In commercial setting, >90% of patients who 5 initiated t
Slide 10: Multiple clinical data milestones anticipated in 2025 and beyond
Multiple clinical data milestones anticipated in 2025 and beyond BLU-808 PROOF-OF-CONCEPT STRATEGY UNIVERSE OF ALLERGIC & INFLAMMATORY DISEASES Move rapidly into areas where targeting KIT has been de-risked Respiratory Skin • Allergic asthma • Chronic urticaria • Chronic spontaneous urticaria • Alle
Slide 11: Strong and durable financial profile entering 2025
Strong and durable financial profile entering 2025 Three Months Three Months FY Ended FY Ended Statement of Operations (unaudited) Ended Ended 12/31/2024 12/31/2023 12/31/2024 12/31/2023 Total revenue $146.4M $72.0M $508.8M $249.4M Net product sales $144.1M $71.0M $479.0M $204.2M Collaboration, lice
Slide 12: Blueprint Medicines
Blueprint Medicines Driving growth and innovation with operational excellence